Trials / Terminated
TerminatedNCT01859351
Phase I Study of WX-037 Alone and in Combination With WX-554 in Solid Tumours
A Phase I Open-label, Dose-escalation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of the PI3K Inhibitor WX-037, Given as a Single Agent and in Combination With the MEK Inhibitor WX-554, in Patients With Solid Tumors
- Status
- Terminated
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 13 (actual)
- Sponsor
- Heidelberg Pharma AG · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to test the safety of escalating doses of the novel PI3K inhibitor WX-037 and to explore its effectiveness in combination with WX-554 which targets mitogen activated protein kinase (MEK1 and MEK2). Preclinical evidence indicates that these two novel compounds could provide targeted inhibition of both pathways to block tumour growth.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | WX-037 | |
| DRUG | WX-554 |
Timeline
- Start date
- 2013-07-01
- Primary completion
- 2014-04-01
- Completion
- 2014-04-01
- First posted
- 2013-05-21
- Last updated
- 2014-05-16
Locations
3 sites across 1 country: United Kingdom
Source: ClinicalTrials.gov record NCT01859351. Inclusion in this directory is not an endorsement.